In the United Kingdom Selzentry is called Celsentri. Both UK and USA versions are the same medicine but with different names.
Prescription Selzentry contains the active ingredient maraviroc for the treatment of HIV-1 in adults and children over 2 years old (22 pounds). Selzentry is used in combination with other HIV medicines when the virus becomes CCR5 tropic, which is determined by blood tests. CCR5 tropic is where the HIV virus attaches to CCR5 proteins on the surface of infected cells.
Selzentry is available in a broad range of strengths and as a liquid. The adult dose of Selzentry is 150mg, 300mg, or 600mg two times per day depending upon the other medicines taken alongside of Selzentry. In children, the dose of Selzentry is based upon the weight of the child.
Selzentry is not a cure for HIV or AIDS but it can help sustain the immune system holding off the virus, thus reducing damage and related infections and associated diseases.
In 2019, when comparing Selzentry cost to USA Selzentry coupon price, InsulinHub was found to offer a discount of approximately 40% in Selzentry savings.
Buy Selzentry from InsulinHub.com for the best Selzentry cost.
Information about Selzentry (Maraviroc)
Selzentry (Maraviroc) is a prescription medication used in the treatment of HIV-1 infection. It is an antiretroviral drug that works by blocking a protein called CCR5 on the surface of immune cells. By inhibiting the CCR5 co-receptor, Selzentry prevents the HIV virus from entering and infecting the cells, helping to control the spread of the virus. Maraviroc is typically used in combination with other HIV medications as part of a comprehensive treatment plan.
Product Highlights
Specifically for patients with CCR5-tropic HIV-1. It is used in combination with other antiretroviral agents to help control HIV replication and improve immune system function.
It is effective only in individuals with CCR5-tropic HIV and should not be used in patients with HIV strains that also use the CXCR4 co-receptor (CCR5/CCR4 or dual-tropic HIV).
Key Ingredient
Maraviroc
Key Benefits
By blocking the CCR5 receptor, Maraviroc prevents HIV from entering and infecting healthy immune cells.
When used in combination with other antiretroviral medications, Selzentry helps to control HIV replication and improve the patient’s immune system function.
Maraviroc has a unique mechanism of action compared to other HIV medications, and it may have a different side effect profile, which could be beneficial for some patients.
Direction of Use
The usual dose of Selzentry is one tablet taken twice daily, with or without food. The exact dosage may depend on factors such as the patient's current antiretroviral regimen and liver function.
The tablet should be taken orally, according to the instructions provided by your healthcare provider. It is important to follow the prescribed dosing schedule for maximum effectiveness.
If you miss a dose, take it as soon as you remember, unless it's almost time for your next dose. Do not take two doses at the same time to compensate for a missed dose.
When given with strong CYP3A inhibitors (with or without CYP3A inducers) including PIs (except tipranavir/ritonavir), delavirdine
150 mg twice daily
With NRTIs, tipranavir/ritonavir, nevirapine, and other drugs that are not strong CYP3A inhibitors or CYP3A inducers
300 mg twice daily
With CYP3A inducers including efavirenz (without a strong CYP3A inhibitor)
600 mg twice daily
Safety Concerns
Common side effects of Selzentry can include coughing, fever, dizziness, fatigue, and rashes. Serious side effects can include liver damage, cardiovascular events (such as heart attack or stroke), and an increased risk of infections.
Maraviroc can cause liver toxicity, so liver function should be monitored during treatment, particularly in patients with pre-existing liver disease.
Some patients may experience cardiovascular problems, such as orthostatic hypotension (a drop in blood pressure when standing up) or an increased risk of heart-related events.
When starting HIV treatment, some patients may experience an inflammatory response due to the immune system improving. This may cause worsening of opportunistic infections.
Avoid Selzentry (Maraviroc) If
Do not use Selzentry if you are allergic to maraviroc or any of the other ingredients in the medication.
Selzentry should not be used in patients with severe liver problems, as it may worsen liver function.
Avoid Selzentry in patients with certain heart conditions, particularly those who have a history of cardiovascular events, as the medication may increase the risk of heart-related problems.
Selzentry is not effective in patients with dual-tropic or CXCR4-tropic HIV, as the drug specifically targets the CCR5 receptor. A tropism test should be performed before starting treatment to ensure the virus is CCR5-tropic.
Although not fully contraindicated, Selzentry should be used during pregnancy only if the potential benefit justifies the potential risk. Consult with a healthcare provider to weigh the risks and benefits in pregnancy.
